Despite demand, historically the development of oral biologics has been hindered by the physiological and biochemical barriers of the GI tract
This product is sold for laboratory research use only
The total number of GLP-1 users is expected to increase significantly over the coming years as pharma expands production capacity, reduces prices, develops new products with fewer side effects, and offers more user-friendly dosage forms
It has therefore been a major interest to develop profiles for personalized medicine or treatment strategies including biomarkers for risk stratifications, which could end in a scenario where treatments are targeted to the patients that have the highest likelihood of responding
We can also blunt or even avoid the nasty side effects by improving the ability of your digestive tract to work efficiently
Higher doses often yield stronger efficacy but also greater gastrointestinal issues, tolerability drop-outs, etc